Status:

TERMINATED

Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

Lead Sponsor:

Amgen

Conditions:

Crohn's Disease

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (...

Eligibility Criteria

Inclusion

  • Diagnosed with ileal, ileo-colonic, or colonic Crohn's disease for a minimum of 6 months prior to initiating study drug
  • Moderately to severely active Crohn's disease, as defined by a CDAI score \>250 and \< 450 at baseline
  • Evidence of active inflammation

Exclusion

  • Short bowel syndrome
  • Stricture with obstructive symptoms within 3 months
  • Bowel surgery within 3 months
  • Ileostomy and/or colostomy
  • Any gastric or intestinal pouch
  • Ulcerative colitis
  • Evidence of an infected abscess
  • Bowel perforation or evidence of noninflammatory obstruction during the 6 months
  • Stool positive for C. Difficile toxin at screening
  • Presence of active infection requiring treatment
  • Serious infection within 8 weeks
  • Significant concurrent medical conditions
  • Pregnant or breast feeding
  • Significant Laboratory abnormalities
  • Any anti-tumor necrosis factor (TNF) agent within 2 months
  • Steroid enemas within 2 weeks
  • Tysabri (natalizumab) within 1 year
  • Biologic agents (eg, ustekinumab), experimental procedures, or live vaccines within 3 months
  • Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin),thalidomide or tacrolimus within 2 months

Key Trial Info

Start Date :

November 9 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 15 2011

Estimated Enrollment :

130 Patients enrolled

Trial Details

Trial ID

NCT01150890

Start Date

November 9 2010

End Date

October 15 2011

Last Update

January 3 2022

Active Locations (50)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (50 locations)

1

Research Site

Birmingham, Alabama, United States

2

Research Site

Dothan, Alabama, United States

3

Research Site

Lowell, Arkansas, United States

4

Research Site

Jacksonville, Florida, United States